XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.06

+0.3%

Dec 26 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aknahow who wrote (8428)	1/22/1999 4:39:00 PM
From: Biomaven	Read Replies (1) of 17367

george, A perfect example of the dangers of subset analysis. From a description of ABTI's previous study: In the upper GI surgery stratum (non-colorectal, n=391), there was a prominent and statistically significant reduction in serious post-operative infections in both Betafectin dose groups versus placebo. The percentage of patients with serious infections decreased 39% in the two treated groups compared to placebo; 46 of 129 (36%) patients in the placebo group experienced serious infection, while 29 of 132 (22%) patients in the 0.5 mg/kg Betafectin group and 28 of 130 (22%) patients in the 1.0 mg/kg Betafectin group experienced serious infection (p=0.01). This key result provided the basis for the ongoing confirmatory trial in upper GI surgery patients. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next